A Review on Biomolecular Mechanisms of Parkinson?óÔé¼Ôäós Disease
Main Article Content
Abstract
Degeneration of catecholaminergic (dopamine) neurons in the Substantia Nigra pars compacta of the basal ganglia results in Parkinson?óÔé¼Ôäós disease (PD). The drug of choice is L-dopa, anticholinergics, amantadine, monoamine oxidase-B inhibitors, dopamine agonists, and catechol O-methyl transferase inhibitors are used. Therapeutic strategies are currently managing the symptoms of PD, but not curing the disease. This review draws insights on the molecular mechanisms driving the loss of brain cells in PD.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.